Private idiotypes located on light and heavy chains of human myeloma proteins characterized by monoclonal antibodies

Hybridoma

Volumn 25, Issue 6, 2006, Pages 329-335

  Hajighasemi, Fatemeh ^a,b   Gharagozlou, Soheila ^a   Ghods, Roya ^a,c   Khoshnoodi, Jalal ^a   Shokri, Fazel ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c Avesina Research Institute   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN SUBCLASS; MONOCLONAL ANTIBODY; PARAPROTEIN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONE; CELL FUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA; IMMUNOBLOTTING; MONITORING; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SERUM; SPLEEN CELL;

MURINAE;

EID: 33845912421     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2006.25.329     Document Type: Article

References (28)

1. Greenspan NS and Bona CA: Idiotypes: Structure and immunogenicity. FASEB J 1993;7:437-444.
2. Shokri F, Mageed RA, Richardson P, and Jefferis R: Modulation and high frequency expression of autoantibody-associated cross-reactive idiotypes linked to the VHI subgroup in CD5-expressing B lymphocytes from patients with chronic lymphocytic leukaemia (B-CLL). Scand J Immunol 1993;37:673-679.
3. Shokri F, Mageed RA, Richardson P, and Jefferis R: Immunophenotypic and idiotypic characterization of the leukaemic B-cells from patients with prolymphocytic leukaemia: Evidence for a selective expression of immunoglobulin variable region (IGV) gene products. Leuk Res 1993;178:669-676.
4. Shokri F, Mageed RA, Maziak BR, Talal N, Amos N, Williams BD, and Jefferis R: Lymphoproliferation in primary Sjogren's syndrome. Evidence of selective expansion of a B cell subset characterized by the expression of cross-reactive idiotypes. Arthritis Rheum 1993;368:1128-1136.
5. Jefferis R: What is an idiotype? Immunol Today 1993;143:119-121.
6. Sandstrom P, Johansson A, Ullen A, Rathsman S, Riklund-Ahlstrom K, and Stigbrand T: Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting. Clin Cancer Res 1999;5(10 Suppl):3073s-3078s.
7. Brown S, Dilley J, and Levy R: Immunoglobulin secretion by mouse X human hybridomas: An approach for the production of anti-idiotype reagents useful in monitoring patients with B cell lymphoma. J Immunol 1980;125:1037-1043.
8. Cavenaugh JS, Wang HK, Sha J, Hansen C, Papangkorn K, Smith RS, and Herron JN: How well can an idiotope peptide mimic replace its parent idiotype in a synthetic peptide vaccine? Pharm Res 2004;21:1480-1488.
9. Stritzke J, Zunkel T, Steinmann J, Schmitz N, Uharek L, and Zeis M: Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br J Haematol 2003;120:27-35.
10. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, and Hawkins RE: Immunization with a recombinant adenovirus encoding a lymphoma idiotype: Induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002;168:3983-3991.
11. Terness P, Welschof M, Moldenhauer G, Jung M, Moroder L, Kirchhoff F, Kipriyanov S, Little M, and Opelz G: Idiotypic vaccine for treatment of human B-cell lymphoma. Construction of IgG variable regions from single malignant B cells. Hum Immunol 1997;56:17-27.
12. Veelken H and Osterroth F: Vaccination strategies in the treatment of lymphomas. Oncology 2002;62:187-200.
13. Rezvany MR, Jeddi-Tehrani M, Rabbani H, Ruden U, Hammarstrom L, Osterborg A, Wigzell H, and Mellstedt H: Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2000;111:230-238.
14. Yildirim T, Basalp A, Yucel F, Manav AI, and Sezen IY: Generation of anti-idiotypic antibodies that mimic HBsAg and vaccination against hepatitis B virus. Hybrid Hybridomics 2004;23:192-197.
15. Depraetere H, Depla E, Haelewyn J, and De Ley M: An anti-idiotypic antibody with an internal image of human interferon-gamma and human interferon-gamma-like antiviral activity. Eur J Biochem 2000;267:2260-2267.
16. Kolesnikov AV, Kozyr AV, Alexandrova ES, Koralewski F, Demin AV, Titov MI, Avalle B, Tramontano A, Paul S, Thomas D, Gabibov AG, and Friboulet A: Enzyme mimicry by the antiidiotypic antibody approach. Proc Natl Acad Sci USA 2000;97:13526-13531.
17. Wagner U, Kohler S, Prietl G, Giffels P, Schmidt-Nicolai S, Schlebusch H, Grunn U, Bender H, Biersack HJ, De Potter C, Krebs D, and Wallwiener D: Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]. Zentralbl Gynakol 1999;121:190-195.
18. Li G, Xie L, Zhou G, Fu H, Zhou J, and Sun Q: A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients. Chin Med J (Engl) 2002;115:567-570.
19. Herlyn D, Benden A, Kane M, Somasundaram R, Zaloudik J, Sperlagh M, Marks G, Hart E, Ralph C, and Wettendorff M: Anti-idiotype cancer vaccines: Pre-clinical and clinical studies. In Vivo 1991;5:615-623.
20. Hadji-Ghasemi F, Gharagozlou S, Ghods R, Roohi A, Khoshnoodi J, and Shokri F: Generation and characterization of a mouse monoclonal antibody with specificity similar to staphylococcal protein A (SPA). Hybrid Hybridomics 2003;22:33-39.
21. Davie JM, Seiden MV, Greenspan NS, Lutz CT, Bartholow TL, and Clevinger BL: Structural correlates of idiotopes. Ann Rev Immunol 1986;4:147-165.
22. Walker LC, Dhut S, Gregory WM, and Habeshaw JA: Cross-reactive variable-region associated epitopes of human IgG1 lambda paraprotein detected by a monoclonal antibody panel. Immunology 1987;61:247-254.
23. Ling NR, Lowe J, and Jefferis R: Monoclonal antibodies to the idiotypic determinants of a human IgG paraprotein: Evidence for complexity of the anti-idiotype response. Clin Exp Immunol 1982;48:1-7.
24. Sarnesto A, Ranta S, Seppala IJ, and Makela O: Relative immunogenicity in mice of different regions of the human IgG. Scand J Immunol 1983;17:507-511.
25. Lowe J, Hardie D, Jefferis R, Ling NR, Drysdale P, Richardson P, Raykundalia C, Catty D, Appleby P, Drew R, and Maclennan IC: Properties of monoclonal antibodies to human immunoglobulin kappa and lambda chains. Immunology 1981;42:649-659.
26. Fredriksen AB, Sandlie I, and Bogen B: DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 2006;13:776-785.
27. Bendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, Perez-Simon JA, Rodriguez-Caballero A, Garcia-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, and Orfao A: Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006;47:29-37.
28. Sahota SS, Townsend M, and Stevenson FK: Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Methods Mol Med 2005;113:105-119.